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Astrocytic processes at the synapse contribute to neurotransmission, but we understand little about
their formation and differentiation. In this issue of Neuron, Yang et al. show that presynaptic input induces
expression of the predominant glial transporter involved in glutamate clearance, and this induction involves
the transcription factor kappa B-binding protein.Astrocytes influence synaptic transmis-
sion in many ways. They secrete distinct
factors that promote synaptogenesis,
neurotransmitter release, and postsyn-
aptic receptors (Barres, 2008). In addition,
they release so-called gliotransmitters in
response to stimulation and contribute to
the calcium waves that correlate with
blood flow (Volterra and Meldolesi, 2005;
Haydon andCarmignoto, 2006). However,
they also participate directly in synaptic
transmission through the expression of
high-affinity transporters for neurotrans-
mitters.
In general, plasma membrane neuro-
transmitter transporters serve two distinct
but related functions. First, they limit
signaling by the released transmitter,
either temporally in the case of neuromo-
dulators such as monoamines or spatially
in the case of glutamate. The excitatory
amino acid transporters (EAATs) control
spillover of glutamate from one synapse
to another (Bergles et al., 1999). Second,
plasma membrane transporters serve to
recycle the released transmitter for pack-
aging and subsequent rerelease. In most
cases, these transporters are expressed
at the nerve terminal, where they are well
positioned to serve both functions. In
contrast, themajor EAAT isoformsGLAST
(human EAAT1) and GLT1 (human EAAT2)
areexpressedbyglia and localize to astro-
cytic processes that reside at varying
distances from the synapse. The EAATs
thus require additional mechanisms to
recycle their accumulated glutamate
back to neurons through the so-called
glutamine-glutamate cycle (Chaudhry
et al., 2002b) as well as to position them
near the synapse for clearance.
In light of their physiological role, the
EAATs have attracted considerable atten-
tion in termsof their potential for regulation,and much of this work has focused on
membrane trafficking (Robinson, 2006). In
the case of EAAT3, a neuronal isoform,
stimulation of extrasynaptic receptors
may cause insertion of more transporter,
thus limiting spillover. Changes in the
expression of EAATs may also contribute
to disease. Loss of the most abundant
isoform, GLT1, causes seizures and
excitotoxicity (Tanaka et al., 1997), and
increased EAAT expression may protect
against neural degeneration (Rothstein
et al., 2005). Interestingly, previous work
in primary astrocyte culture has shown
that neurons induce the expression of
GLT1 (Gegelashvili et al., 1997; Swanson
et al., 1997).
In this issue ofNeuron, Yang et al. char-
acterize themechanism bywhich neurons
induce glial expression of GLT1 (Yang
et al., 2009). Processes of cortical neurons
plated in one chamber of a microfluidic
device enter a second chamber contain-
ing astrocytes and induce local expres-
sion of GLT1. Contact is not absolutely
required for this effect, but does correlate
with higher levels of GLT1, and more
processes correlatewith abigger increase
in transporter expression. The authors
then took advantage of BAC transgenic
mice expressing GFP under control of
GLT1 regulatory sequences (Regan
et al., 2007) to show that the induction of
GLT1 occurs at a transcriptional level.
Tetrodotoxin can block the increase in
GLT1 expression, suggesting that the
effect dependsonactivity andmay involve
neurotransmitter release. Consistent with
a role for released glutamate suggested
bypreviouswork (Duan et al., 1999), gluta-
mate receptor antagonists block the effect
of neuronal processes on GLT1 expres-
sion, and metabotropic receptors appear
particularly important, although AMPA-Neurontype receptors may contribute. The ability
of antagonists for multiple glutamate
receptors to each inhibit GLT1 induction
is surprising and suggests that multiple
signaling systems may be required for
the effect.
The authors further used the BAC trans-
genic mice to understand the transcrip-
tional regulation of GLT1 by neurons. In
this case, they transfected cultures from
the transgenic mice with a DsRed reporter
under the control of GLT1 regulatory
sequences, showing that thesesequences
confer appropriate expression of the
reporter and induction by neurons. The
analysis of serial deletions then identified
a region required for bothbasal expression
and neuronal induction. Focusing their
attention on three highly conserved
sequences within this region, the authors
mutagenized each individually and found
that only one (GGGTGGGTGT) dramati-
cally affects expression. Although the
promoter for GLT1 also contains multiple
binding sites for the transcription factor
nuclear factor kappa B (NFkB), mutation
of these sites apparently had no effect.
In an elegant series of experiments, the
authors extended the characterization
in vivo. Adeno-associated viruses (AAV)
encodingDsRedunder the control of either
the wild-type GLT1 promoter or the unre-
sponsive mutant were injected into the
ventricle of neonatal BAC transgenic
mice, and expression of the reporter
was assessed 3 weeks later. Although
both constructs conferred expression in
neurons, only the wild-type promoter
conferred expression in astrocytes, con-
firming the importance of this sequence
specifically for the inductionofGLT1 inglia.
To identify the protein that interactswith
this motif, the authors used a gel mobility
shift assay. Nuclear extracts produce61, March 26, 2009 ª2009 Elsevier Inc. 811
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Previewsa specific band that increases frombirth to
3 weeks, correlating with the transcrip-
tional activation of GLT1 over this time.
Mass spectrometry of the isolated protein
identified it as the kappa B motif-binding
phosphoprotein (KBBP), which is identical
to the human heterogeneous nuclear ribo-
nucleoprotein hnRNP K, a protein impli-
cated in a number of cellular phenomena
including RNA splicing as well as tran-
scription (Bomsztyk et al., 2004). Surpris-
ingly, the kappa B (kB) enhancer element
recognized by KBBP (GGGGACTTTCC)
is not highly homologous to the sequence
identified in GLT1. Nonetheless, the kB
enhancer can compete out binding to the
sequence in GLT1, and mutation of only
the 50 guanosine residues conserved in
both motifs suffices to eliminate GLT1
promoter activity, pointing to these resi-
dues as particularly important.
KBBP is widely expressed by neurons
as well as astrocytes, but its expression
in astrocytes correlates strongly with
GLT1. Using the BAC transgenic mice,
the authors showed that KBBP upregu-
lates with GFP (and GLT1) in GFP+ cells
during early postnatal development. In
culture, neurons also induce expression
of KBBP by astrocytes. Further, AAV en-
coding antisense RNA for KBBP injected
in vivo appear to knock down the expres-
sion of GFP aswell as KBBP. Overexpres-
sion of KBBP in culture also upregulates
GLT1, but only in the presence of neurons.
Taken together, the results strongly
suggest a role for KBBP in the transcrip-
tional regulation of GLT1 by neurons.
To test a role for KBBP in neuronal regu-
lation of GLT1 expression in vivo, Yang
et al. used a series of lesion models. In
the BAC transgenic mice, transection of
the corticospinal tract causes a dramatic
downregulation of KBBP, GLT1, and the
GFP reporter below the site of the lesion.
Unilateral administration of the neurotoxin
ricin to peripheral nerve also downregu-
lates KBBP and GLT1 in the ipsilateral
ventral horn of the spinal cord, presum-
ably due to the loss of axon collaterals
within the cord. Finally, the authors mated
the GLT1-GFP BAC transgenic mice to
other transgenic mice expressing the812 Neuron 61, March 26, 2009 ª2009 ElsevG93A mutant of superoxide dismutase
(SOD1) that have served as a model for
human ALS and already been demon-
strated to show a downregulation of
GLT1 early in the course of disease (How-
land et al., 2002). The ventral horn of these
double-transgenic animals indeed shows
a downregulation of KBBP that strongly
correlates with both GLT1 and the GFP
reporter.
Taken together, the results indicate that
KBBP participates in a signaling pathway
through which presynaptic input activates
the expression ofGLT1 in glia. The elegant
combination of BAC transgenic mice with
a sophisticated culture system, reporter
assay, biochemistry, and disease models
has thus led to the identification of a novel
element in signaling through a physiologi-
cally important pathway. Nonetheless,
many questions remain. In addition to
glutamate, membrane contact appears
to play a role, and we do not know the
factors responsible. Further, the mecha-
nism by which glutamate receptor activa-
tion induces KBBP, and indeed the role of
multiple glutamate receptors in this
process, remains poorly understood.
Since KBBP is widely expressed, it will
be particularly interesting to determine
why astrocytes specifically depend on
neurons for the expression of KBBP, and
whether this in turn involves transcrip-
tional activation of KPPB or a posttran-
scriptional mechanism such as increased
protein stability. It will also be very impor-
tant to determine how the activation of
GLT1 fits into the more general process
of glial differentiation at the synapse.
The regulation of GLT1 expression by
presynaptic input also raises important
questions about cause and effect in neural
degeneration. It is very clear that loss of
GLT1 causes severe toxicity, and downre-
gulationmay occur in ALS. However, both
previous work and the current report
(Yang et al., 2009) suggest that the down-
regulation observed may reflect rather
than cause neuronal loss. Indeed, down-
regulation in the absence of neural input
might have less deleterious conse-
quences than in the intact state, where
the release of more glutamate has greaterier Inc.potential to produce toxicity. Neuronal
regulation presumably serves to coordi-
nate glutamate clearance with glutamate
release. However, a defect in the signaling
mechanismmight trigger thedegenerative
process without a primary disorder of the
neuron, and even secondary changes in
EAAT expression may propagate the
neuronal injury.
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